Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …

Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …

PURPOSE Nivolumab received US Food and Drug Administration approval as a single
agent or in combination with ipilimumab in patients with microsatellite instability …

Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

PURPOSE: IMpower133 (ClinicalTrials. gov identifier: NCT02763579), a randomized,
double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed …

Importance Most patients with hepatocellular carcinoma (HCC) are diagnosed with
advanced disease not eligible for potentially curative therapies; therefore, new treatment …

Background First-line durvalumab plus etoposide with either cisplatin or carboplatin
(platinum–etoposide) showed a significant improvement in overall survival versus platinum …

Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer. Although SCLC is
characterised by rapid responses to chemotherapy (ChT) and sensitivity to radiotherapy …

Background Lung cancer is made up of distinct subtypes, including non–small-cell lung
cancer (NSCLC) and small-cell lung cancer (SCLC). Although overall mortality from lung …

Cancer is associated with higher morbidity and mortality and is the second leading cause of
death in the US. Further, in some nations, cancer has overtaken heart disease as the …